Literature DB >> 32108991

Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Judicael Fazavana1, Teresa M Brophy1, Alain Chion1, Niamh Cooke2, Virginie Terraube2, Justin Cohen3, Chuenlei Parng3, Debra Pittman4, Orla Cunningham2, Matthew Lambert2, James S O'Donnell1,5, Jamie M O'Sullivan1.   

Abstract

BACKGROUND: Previous studies have demonstrated that the A1A2A3 domains of von Willebrand factor (VWF) play a key role in regulating macrophage-mediated clearance in vivo. In particular, the A1-domain has been shown to modulate interaction with macrophage low-density lipoprotein receptor-related protein-1 (LRP1) clearance receptor. Furthermore, N-linked glycans within the A2-domain have been shown to protect VWF against premature LRP1-mediated clearance. Importantly, however, the specific regions within A1A2A3 that enable macrophage binding have not been defined. OBJECTIVE AND METHODS: To address this, we utilized site-directed PEGylation and introduced novel targeted N-linked glycosylation within A1A2A3-VWF and subsequently examined VWF clearance.
RESULTS: Conjugation with a 40-kDa polyethylene glycol (PEG) moiety significantly extended the half-life of A1A2A3-VWF in VWF-/- mice in a site-specific manner. For example, PEGylation at specific sites within the A1-domain (S1286) and A3-domain (V1803, S1807) attenuated VWF clearance in vivo, compared to wild-type A1A2A3-VWF. Furthermore, PEGylation at these specific sites ablated binding to differentiated THP-1 macrophages and LRP1 cluster II and cluster IV in-vitro. Conversely, PEGylation at other positions (Q1353-A1-domain and M1545-A2-domain) had limited effects on VWF clearance or binding to LRP1.Novel N-linked glycan chains were introduced at N1803 and N1807 in the A3-domain. In contrast to PEGylation at these sites, no significant extension in half-life was observed with these N-glycan variants.
CONCLUSIONS: These novel data demonstrate that site specific PEGylation but not site specific N-glycosylation modifies LRP1-dependent uptake of the A1A2A3-VWF by macrophages. This suggests that PEGylation, within the A1- and A3-domains in particular, may be used to attenuate LRP1-mediated clearance of VWF.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  PEGylation; clearance; glycosylation; low density lipoprotein receptor-related protein; von Willebrand factor

Mesh:

Substances:

Year:  2020        PMID: 32108991      PMCID: PMC7645976          DOI: 10.1111/jth.14785

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  30 in total

Review 1.  Elevated factor VIII levels and risk of venous thrombosis.

Authors:  P Vince Jenkins; Orla Rawley; Owen P Smith; James S O'Donnell
Journal:  Br J Haematol       Date:  2012-04-25       Impact factor: 6.998

Review 2.  von Willebrand factor: the old, the new and the unknown.

Authors:  P J Lenting; C Casari; O D Christophe; C V Denis
Journal:  J Thromb Haemost       Date:  2012-12       Impact factor: 5.824

3.  A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance.

Authors:  Soracha E Ward; Jamie M O'Sullivan; Clive Drakeford; Sonia Aguila; Christopher N Jondle; Jyotika Sharma; Padraic G Fallon; Teresa M Brophy; Roger J S Preston; Paul Smyth; Orla Sheils; Alain Chion; James S O'Donnell
Journal:  Blood       Date:  2017-12-27       Impact factor: 22.113

4.  von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo.

Authors:  O Rawley; J M O'Sullivan; A Chion; S Keyes; M Lavin; N van Rooijen; T M Brophy; P Fallon; R J S Preston; J S O'Donnell
Journal:  J Thromb Haemost       Date:  2015-04-13       Impact factor: 5.824

5.  Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.

Authors:  Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

Review 6.  Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance.

Authors:  V Terraube; J S O'Donnell; P V Jenkins
Journal:  Haemophilia       Date:  2009-04-16       Impact factor: 4.287

7.  Significant gynecological bleeding in women with low von Willebrand factor levels.

Authors:  Michelle Lavin; Sonia Aguila; Niall Dalton; Margaret Nolan; Mary Byrne; Kevin Ryan; Barry White; Niamh M O'Connell; Jamie M O'Sullivan; Jorge Di Paola; Paula D James; James S O'Donnell
Journal:  Blood Adv       Date:  2018-07-24

8.  An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.

Authors:  Peter J Lenting; Erik Westein; Virginie Terraube; Anne-Sophie Ribba; Eric G Huizinga; Dominique Meyer; Philip G de Groot; Cécile V Denis
Journal:  J Biol Chem       Date:  2003-11-12       Impact factor: 5.157

Review 9.  von Willebrand factor clearance - biological mechanisms and clinical significance.

Authors:  Jamie M O'Sullivan; Soracha Ward; Michelle Lavin; James S O'Donnell
Journal:  Br J Haematol       Date:  2018-10       Impact factor: 6.998

10.  N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance.

Authors:  Alain Chion; Jamie M O'Sullivan; Clive Drakeford; Gudmundur Bergsson; Niall Dalton; Sonia Aguila; Soracha Ward; Padraic G Fallon; Teresa M Brophy; Roger J S Preston; Lauren Brady; Orla Sheils; Michael Laffan; Thomas A J McKinnon; James S O'Donnell
Journal:  Blood       Date:  2016-08-23       Impact factor: 22.113

View more
  3 in total

Review 1.  VWF, Platelets and the Antiphospholipid Syndrome.

Authors:  Shengshi Huang; Marisa Ninivaggi; Walid Chayoua; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

2.  The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial.

Authors:  Katarina D Kovacevic; Jürgen Grafeneder; Christian Schörgenhofer; Georg Gelbenegger; Gloria Gager; Christa Firbas; Peter Quehenberger; Petra Jilma-Stohlawetz; Andrea Bileck; Shuhao Zhu; James C Gilbert; Martin Beliveau; Bernd Jilma; Ulla Derhaschnig
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

3.  Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.

Authors:  Shujuan Xu; Fang Wang; Hui Li; Ya Wang; Dongzhong Fang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.